The universal autoimmune hemolytic anemia treatment market report is used to analyse and evaluate performances of a company within a market. It studies effectiveness of a sales force and helps in ...

THE danger of hemolytic streptococcus respiratory infection to persons who are susceptible to rheumatic fever is well recognized. Since with present knowledge there are inherent difficulties in ...

NEW ORLEANS — Patients with paroxysmal nocturnal hemoglobinuria who received iptacopan vs. standard therapy had clinically meaningful and significant improvement in symptoms, results of the phase 3 ...

The global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market is worth US$ 638.96 Million in the year 2023 and is expected to reach US$ 1598 Million by the year 2033 at a CAGR of 9.6% between ...

Enjaymo is the first-and-only approved therapeutic option approved for hemolytic anemia in adult patients with cold agglutinin disease Enjaymo is currently the only approved treatment for CAD and is a ...

Intravenous immunoglobulin therapy (IVIG) is a critical treatment modality in the management of a spectrum of immunodeficiencies, autoimmune disorders, and inflammatory conditions. Derived from pooled ...

Progressive B-cell chronic lymphocytic leukemia (B-CLL) is often complicated by autoimmune hemolytic anemia (AIHA), which in some cases may be refractory to conventional therapy such as ...

A team of physicians from Germany, Canada, and France reports on the successful treatment of three young children who were suffering from a severe hemolytic-uremic syndrome (HUS) after an infection ...

P-Glycoprotein Inhibitor Valspodar (PSC 833) Increases the Intracellular Concentrations of Daunorubicin In Vivo in Patients With P-Glycoprotein–Positive Acute Myeloid Leukemia PURPOSE: Past reports ...

In the online version of the New England Journal of Medicine, physicians and scientists in Heidelberg, Montreal, and Paris reported on the successful treatment of three young children who were ...

TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (OTCQB: “ABPI”) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune™, the ...